Hyuga Primary Care (7133) · RiskRestated
Risk that consumption-tax rates and drug-price standards will not move in tandem
First written in FY2022. 1 of 2 entries say "Restated". Latest entry: FY2025.
2entries
4years
0from disclosures
How it moved
Same theme, other companies
Earnings impact on the dispensing business from consumption tax rate changes and differences in drug price pass-throughA theme 7 companies write about · 7 as a headwind · 0 as a tailwind
4 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2025RestatedAnnual report
「If consumption tax rates are revised in the future and the official drug price schedule does not track the rate of change in consumption tax rates, this may affect the performance and other aspects of our group.」
The risk of an impact on earnings from a mismatch between consumption tax rates and the official drug price schedule continues to be disclosed. - FY2022First statedAnnual report
「If consumption tax rates are revised in the future and the official drug price schedule does not track the rate of change in consumption tax rates, this may affect our performance and other aspects.」
Against the background that dispensing revenue is tax-exempt while drug purchases are taxable, the mismatch between revisions to consumption tax rates and the official drug price schedule is identified as a risk.